Inspire Medical Systems, Inc. Common Stock (INSP)
87.77
+3.19 (3.77%)
NYSE · Last Trade: Aug 17th, 9:34 PM EDT
Shares of medical technology company Inspire Medical Systems (NYSE:INSP)
jumped 3.3% in the morning session after the stock extended its positive momentum as a recent announcement of a $200 million share repurchase program boosted investor confidence. This buyback program, authorized by the company's board, suggests that management believes the stock is undervalued and is a way to signal their commitment to returning value to shareholders despite the recent operational challenges and revised financial guidance.
Via StockStory · August 15, 2025
Via Benzinga · August 15, 2025
Shares of medical technology company Inspire Medical Systems (NYSE:INSP)
jumped 4% in the afternoon session after its Board of Directors announced a share buyback program of up to $200 million. Share buyback programs are often a sign that a company's leadership believes its stock is undervalued. This sentiment was echoed by CEO Tim Herbert, who stated, “we remain confident that our growth prospects are substantial… and that our stock is undervalued.” The plan authorizes the company to repurchase up to 8.6% of its shares. This announcement comes after the stock price declined following its recent second-quarter earnings report, suggesting management views the current price as an attractive investment. Adding to the positive momentum, the broader market also rallied on favorable inflation data, which may have provided an additional tailwind for the stock.
Via StockStory · August 13, 2025
Inspire Medical Systems Stock Slumps On Downgrades, Price Target Cuts: Retail Believes Stock Is Way Oversoldstocktwits.com
Via Stocktwits · August 5, 2025
Medical technology company Inspire Medical Systems (NYSE:INSP) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.8% year on year to $217.1 million. On the other hand, the company’s full-year revenue guidance of $905 million at the midpoint came in 4.6% below analysts’ estimates. Its GAAP loss of $0.12 per share was significantly below analysts’ consensus estimates.
Via StockStory · August 13, 2025
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve.
Via StockStory · August 12, 2025
Inspire Medical's chart structure signals weakness after a major breakdown. Here's why investors may want to avoid the stock until 2028.
Via Benzinga · August 7, 2025
US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down & Fed may cut rates.
Via Benzinga · August 6, 2025
Via Benzinga · August 6, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Via Chartmill · August 5, 2025
Via Benzinga · August 5, 2025
Inspire Medical stock falls as Q2 earnings beat is overshadowed by guidance cut and slower U.S. rollout of its newly approved Inspire V system.
Via Benzinga · August 5, 2025
Shares of medical technology company Inspire Medical Systems (NYSE:INSP)
fell 41.3% in the afternoon session after the company slashed its full-year revenue and profit forecasts, a move that overshadowed a second-quarter earnings beat.
Via StockStory · August 5, 2025
Via Benzinga · August 5, 2025
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · August 5, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · August 5, 2025
The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug.
Via Investor's Business Daily · August 5, 2025
Via Benzinga · August 5, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · August 5, 2025
Via Benzinga · August 5, 2025
Via Benzinga · August 5, 2025